Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

PHASE4TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Attention-Deficit/Hyperactivity DisorderAttention Deficit DisorderInsomniaSleep Disorders
Interventions
DRUG

Guanfacine extended-release tablets

Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated

DRUG

Placebo comparator

Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).

Trial Locations (2)

08619

Children's Specialized Hospital, Hamilton

08755

Children's Specialized Hospital, Toms River

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Children's Specialized Hospital

OTHER